YCCI News

The Yale School of Public Health’s annual Dean’s Lecture and Program on Aging seminar was delivered this year by Harvard Professor David Grabowski, a leading national expert in health care policy and long-term care.

Teplizumab can change the course of type 1 diabetes, one of the most common chronic diseases of childhood, and the lives of those who might develop the disease.

The therapy will cost nearly $200,000. But it’s the first treatment in 100 years to alter the course of the disease, which usually begins in adolescence.

Self-reported psychological distress, defined as symptoms of depression, anxiety, posttraumatic stress disorder (PTSD), or perceived psychosocial stress, was associated with a 28% greater risk of cardiovascular morbidity and mortality, a meta-analysis finds.

The field of genetic testing for cancer is rapidly evolving. Veda N. Giri, MD, the new Chief of the Division of Clinical Cancer Genetics at Smilow Cancer Hospital and Yale Cancer Center is at the evolution’s forefront.

As the new director of Smilow Cancer Hospital’s Sickle Cell Program, Dr. Cecelia “Cece” Calhoun tackles a rare disease with an urgent need for change.

A Yale study found that despite growing investments in health care over the past 20 years, barriers to timely medical care are increasing, as are racial and ethnic disparities in access to health care.

ME/CFS (myalgic encephalomyelitis/chronic fatigue syndrome) is a highly disabling, severe condition that has been largely overlooked and even questioned as an illness by physicians and biomedical researchers for decades. But now, scientists including Yale's Akiko Iwasaki and Harlan Krumholz are finding parallels between post-infection long COVID and ME/CFS.

A Yale Medicine orthopaedic surgeon has developed an innovative procedure that uses a patient’s own stem cells to treat a condition that can cause painful hip fractures.